Dynavax Technologies
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 408
- Market Cap
- $1.4B
- Introduction
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.
Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine
- Conditions
- Hepatitis B
- Interventions
- Biological: HEPLISAV and/or PlaceboBiological: Engerix-B
- First Posted Date
- 2007-02-15
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 2428
- Registration Number
- NCT00435812
Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients
- Conditions
- Hepatitis B
- Interventions
- Biological: Hepatitis B Vaccine (Recombinant)Biological: 1018 ISS immunostimulatory oligonucleotide with HBV surface antigen
- First Posted Date
- 2007-01-25
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 42
- Registration Number
- NCT00426712
- Locations
- 🇺🇸
University of Virginia Health System, Nephrology Clinical Research Center, Charlottesville, Virginia, United States
🇺🇸West Coast Clinical Trials, Costa Mesa, California, United States
🇺🇸Covance, Austin, Texas, United States
A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer
- Conditions
- Colorectal Neoplasms
- Interventions
- Drug: 1018 ISS immunostimulatory oligonucleotide
- First Posted Date
- 2006-11-23
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 14
- Registration Number
- NCT00403052
- Locations
- 🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸Premiere Oncology, Santa Monica, California, United States
🇺🇸Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States
Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults
- Conditions
- Rhinitis, Allergic, Seasonal
- Interventions
- Biological: Histamine baseBiological: Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 738
- Registration Number
- NCT00387738
- Locations
- 🇺🇸
Research Center of Indiana, Indianapolis, Indiana, United States
🇺🇸Clinical Research of The Ozarks, Rolla, Missouri, United States
🇺🇸Atlanta Allergy & Asthma Clinic, Stockbridge, Georgia, United States